PDF(Pubmed)
Abstract：
UNASSIGNED: To analyze the clinical characteristics and correlation of Fournier\'s gangrene induced by sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors, providing references for safe clinical drug use.
UNASSIGNED: The CNKI, WanFang, and PubMed databases were searched, and relevant documents were collected and statistically analyzed. The basic information of patients, drug use information, adverse reactions and outcomes were extracted and analyzed.
UNASSIGNED: A total of 12 patients (8 males and 4 females) were included, with an average age of 55.6 years (ranging from 34 to 72 years). SGLT-2 inhibitors associated with Fournier\'s gangrene include empagliflozin (5 cases), dapagliflozin (5 cases), and canagliflozin (2 cases). Among them, 10 cases reported the time of first medication, ranging from 1 month to 6 years for the occurrence of adverse reactions. The most common concomitant drug was metformin (7 cases). Adverse reactions mainly manifested as redness, swelling and pain in the buttocks, perineum, perianal, scrotum and other positions, accompanied by an increased white blood cell count. Following surgery and antibiotic treatment, all patients showed improved.
UNASSIGNED: Fournier\'s gangrene induced by SGLT-2 inhibitors is rare. If patients using SGLT-2 inhibitors are suspected of having Fournier\'s gangrene, it is recommended to discontinue the drugs immediately and initiate active treatment to ensure clinical safety.
UNASSIGNED: The CNKI, WanFang, and PubMed databases were searched, and relevant documents were collected and statistically analyzed. The basic information of patients, drug use information, adverse reactions and outcomes were extracted and analyzed.
UNASSIGNED: A total of 12 patients (8 males and 4 females) were included, with an average age of 55.6 years (ranging from 34 to 72 years). SGLT-2 inhibitors associated with Fournier\'s gangrene include empagliflozin (5 cases), dapagliflozin (5 cases), and canagliflozin (2 cases). Among them, 10 cases reported the time of first medication, ranging from 1 month to 6 years for the occurrence of adverse reactions. The most common concomitant drug was metformin (7 cases). Adverse reactions mainly manifested as redness, swelling and pain in the buttocks, perineum, perianal, scrotum and other positions, accompanied by an increased white blood cell count. Following surgery and antibiotic treatment, all patients showed improved.
UNASSIGNED: Fournier\'s gangrene induced by SGLT-2 inhibitors is rare. If patients using SGLT-2 inhibitors are suspected of having Fournier\'s gangrene, it is recommended to discontinue the drugs immediately and initiate active treatment to ensure clinical safety.
摘要：
■分析钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂诱导的Fournier坏疽的临床特征和相关性，为临床安全用药提供参考。
■CNKI，万方,搜索了PubMed数据库，并对相关文献进行收集和统计分析。患者的基本信息,药物使用信息,提取并分析不良反应和转归。
■共包括12名患者（8名男性和4名女性），平均年龄为55.6岁（34至72岁）。与Fournier坏疽相关的SGLT-2抑制剂包括依帕列净（5例），达格列净(5例)，和canagliflozin(2例)。其中,10例报告首次用药时间，不良反应的发生时间为1个月至6年。最常见的合并用药是二甲双胍(7例)。不良反应主要表现为发红，臀部肿胀和疼痛，会阴,肛周,阴囊和其他位置，伴有白细胞计数增加。手术和抗生素治疗后，所有患者均显示改善。
■SGLT-2抑制剂诱导的Fournier坏疽很少见。如果使用SGLT-2抑制剂的患者被怀疑患有Fournier坏疽，建议立即停药并开始积极治疗，以确保临床安全。
■CNKI，万方,搜索了PubMed数据库，并对相关文献进行收集和统计分析。患者的基本信息,药物使用信息,提取并分析不良反应和转归。
■共包括12名患者（8名男性和4名女性），平均年龄为55.6岁（34至72岁）。与Fournier坏疽相关的SGLT-2抑制剂包括依帕列净（5例），达格列净(5例)，和canagliflozin(2例)。其中,10例报告首次用药时间，不良反应的发生时间为1个月至6年。最常见的合并用药是二甲双胍(7例)。不良反应主要表现为发红，臀部肿胀和疼痛，会阴,肛周,阴囊和其他位置，伴有白细胞计数增加。手术和抗生素治疗后，所有患者均显示改善。
■SGLT-2抑制剂诱导的Fournier坏疽很少见。如果使用SGLT-2抑制剂的患者被怀疑患有Fournier坏疽，建议立即停药并开始积极治疗，以确保临床安全。
